FDA Accepts Application for COSOPT PF Supplement by THEA PHARMA
The FDA has accepted the supplemental application NDA202667 for COSOPT PF, a glaucoma treatment.
Company
Pharmaceutical intelligence for THEA PHARMA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.